Effect of adalimumab on choroidal thickness and choroidal vascularity index in eyes with non-infectious uveitis using enhanced-depth imaging optical coherence tomography
التفاصيل البيبلوغرافية
العنوان:
Effect of adalimumab on choroidal thickness and choroidal vascularity index in eyes with non-infectious uveitis using enhanced-depth imaging optical coherence tomography
Objective To evaluate the effect of adalimumab (ADA) on choroidal thickness (ChT) and choroidal vascularity index (CVI) in eyes with non-infectious uveitis (NIU). Methods Thirty-seven eyes with NIU, 38 eyes of non-uveitic (NU) patients, and 40 control eyes were included. ADA was used for anti-TNF-naive adult (80mg) or pediatric (40mg) patients with refractory NIU, then 40mg every 2-week (20mg in children p > 0.05). However, calculated CVI values in eyes with NIU (0.63 ± 0.007) were significantly (p p p p > 0.05). Conclusions Decreased CVI in NIU and NU eyes indicates that systemic inflammation affects the choroidal vasculature and perfusion both in the presence and absence of ocular involvement. Although CVI may be used as a possible novel tool in monitoring ocular involvement and progression of NIU, CVI does not seem to be a biomarker for treatment monitoring in NIU.